Portfolio company
KiraGen Bio
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
This biotechnology company develops gene-edited cell therapies to treat solid tumours for patients with glioblastoma and other cancers.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
KiraGen
KiraGen develops multiplex gene-edited CAR-T cell therapies and an AI-driven drug discovery platform for patients with hard-to-treat solid tumours and glioblastoma.
Siren Bio
This company develops immuno-gene therapies combining viral gene delivery and cytokine immunotherapy to treat solid tumours for cancer patients.
Kindling Bio
This company develops a gene therapy platform that engineers tumour cells to display markers for the immune system to treat children with solid tumours.
OverT Bio
This company develops engineered cell therapies and genetic screening platforms to treat patients with solid tumour cancers.
Istari Oncology
This clinical-stage biotechnology company develops immuno-oncology platforms and immunotherapies to treat patients with glioblastoma and other solid tumours.
Trogenix
Trogenix develops precision gene therapies and synthetic super-enhancers for patients with aggressive solid tumours, including glioblastoma and colorectal cancer liver metastases.
OverT
This biotechnology company develops engineered cell therapies for the treatment of solid tumours in cancer patients.
Akiram Therapeutics
This biotech company develops targeted radiopharmaceuticals and radioimmunotherapies for patients with solid tumours and metastatic cancers.